Jonathan Monson compensation by year
Boston Scientific Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $591,848 |
| Bonus | $0 |
| Stock awards | $1,624,898 |
| Option awards | $1,170,504 |
| Non-equity incentive | $840,000 |
| Pension and deferred compensation | $1,817,976 |
| All other | $38,453 |
| Total | $6,083,679 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Boston Scientific Corp. DEF 14A filed March 18, 2026, accession 0000885725-26-000025, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 8,350 | $796,173 | — |
| RSU | 7,066 | $673,743 | — |
| RSU | 3,562 | $339,637 | — |
| RSU | 3,462 | $330,102 | — |
| RSU | 2,116 | $201,761 | — |
| RSU | 990 | $94,397 | — |
| Option | 10,635 | — | $64.99 |
| Option | 10,543 | — | $56.14 |
| Option | 7,165 | — | $106.14 |
| Option | 3,295 | — | $44.19 |
| Option | 6,352 | — | $47.28 |
| Option | 22,173 | — | $104.78 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Boston Scientific Corp.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed March 18, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-10 | I | — | 9,908 | $50.46 | 9,908 |
| 2026-07-01 | Exercise or conversion | — | 2,087 | $0.00 | 40,073 |
| 2026-07-01 | Exercise or conversion derivative | — | 2,087 | $0.00 | 6,263 |
| 2026-07-01 | Tax withholding | — | 1,010 | $43.06 | 39,063 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Boston Scientific’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael Mahoney | Chairman of the Board, President and Chief Executive Officer | $23,532,050 |
| Joseph Fitzgerald | Executive Vice President and Group President, Cardiovascular | $8,042,997 |
| Arthur Butcher | Executive Vice President and Group President, MedSurg and Asia Pacific | $6,534,719 |
| Daniel Brennan | Former Executive Vice President and Chief Financial Officer | $6,282,896 |
| Jonathan Monson · this page | Executive Vice President and Chief Financial Officer | $6,083,679 |
| Jeffrey Mirviss | Former Executive Vice President and President, Peripheral Interventions | $4,159,959 |
| Vance Brown | Executive Vice President, General Counsel and Corporate Secretary | $3,920,644 |
The full Boston Scientific compensation record
free company briefThis page is one person within Boston Scientific's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Boston Scientific's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Boston Scientific's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat